Analysts Getting More Bullish On ViroPharma (article 9/16)
Analysts Getting More Bullish On ViroPharma Following Friday's 28+% Surge On Takeover Chatter
Paul Quintaro, Benzinga Staff Writer
September 16, 2013 11:00 AM
ViroPharma (NASDAQ: VPHM) shares are up about three-quarters of a percent Monday morning on the heels of a 28-plus percent move higher on Friday. Traders in the name were responding to chatter the company had received offers from both Sanofi (NYSE: SNY) and Shire (NASDAQ: SHPG).
Monday morning numerous analysts are commenting and raising price targets on ViroPharma.
■Stifel Nicolaus raised target from $41 to $47, Buy rating maintained.
■Piper Jaffray target from $37 to $46, Overweight maintained.
■Oppenheimer target from $35 to $44, Outperform maintained.
■Mizuho sees value of $45 assuming cost savings if M&A does happen, believes could include a contingent value of $2-3/share related to cinryze.